Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.
Pharmacogenomics
; 17(4): 435-51, 2016 Mar.
Article
in En
| MEDLINE
| ID: mdl-26894782
ABSTRACT
Fluoropyrimidine (FU) and platinum-based chemotherapies are greatly complicated by their associated toxicities. This umbrella systematic review synthesized all systematic reviews that investigated associations between germline variations and toxicity, with the aim of informing personalized medicine. Systematic reviews are important in pharmacogenetics where false positives are common. Four systematic reviews were identified for FU-induced toxicity and three for platinum. Polymorphisms of DPYD and TYMS, but not MTHFR, were statistically significantly associated with FU-induced toxicity (although only DPYD had clinical significance). For platinum, GSTP1 was found to not be associated with toxicity. This umbrella systematic review has synthesized the best available evidence on the pharmacogenetics of FU and platinum toxicity. It provides a useful reference for clinicians and identifies important research gaps.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organoplatinum Compounds
/
Meta-Analysis as Topic
/
Cisplatin
/
Fluorouracil
/
Systematic Reviews as Topic
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Pharmacogenomics
Journal subject:
FARMACOLOGIA
/
GENETICA MEDICA
Year:
2016
Document type:
Article
Affiliation country:
Australia